Inovio Demonstrates 80% 6-Month Progression-Free Survival In P...
PLYMOUTH MEETING, Pennsylvania, Nov. 5, 2019 /PRNewswire-AsiaNet/ -- -- 80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 MonthsInovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today positive interim results from Inovio's Phase 2 study (NCT03491683) of newly diag...
Authors: LATEST ASIANET NEWS RELEASES